Tromso, Norway

Magnus Hattrem

This inventor holds 1 USPTO granted patent and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Vitux Group as. Active years: 2021.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Magnus Hattrem

Introduction

Magnus Hattrem is an accomplished inventor based in Tromso, Norway. He has made significant contributions to the field of pharmaceuticals, particularly in the development of oral pharmaceutical compositions. His innovative work has led to the creation of a unique formulation that enhances the delivery of lipophilic drug substances.

Latest Patents

Hattrem holds a patent for "Oral pharmaceutical dispersion compositions." This invention provides an oral pharmaceutical composition, optionally in dose unit form, comprising a lipophilic drug substance in dispersion in a physiologically tolerable aqueous carrier, preferably an aqueous gel. The drug substance contains a functional electrostatic group having a pKa value of from 2 to 10. The aqueous carrier has a pH at least 0.3 below or above the pKa value, ensuring optimal drug delivery.

Career Highlights

Magnus Hattrem is associated with Vitux Group, where he applies his expertise in pharmaceutical innovations. His work focuses on improving drug formulations to enhance patient outcomes. Hattrem's dedication to research and development has positioned him as a key figure in his field.

Collaborations

Some of Hattrem's notable coworkers include Kurt Ingar Draget and Steinar Johan Engelsen. Their collaborative efforts contribute to the advancement of pharmaceutical technologies and innovations.

Conclusion

Magnus Hattrem's contributions to the pharmaceutical industry through his innovative patent demonstrate his commitment to improving drug delivery systems. His work continues to influence the field and enhance therapeutic options for patients.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…